Certain public-reported immune-mediated adverse events for PD-1 inhibitors in melanoma occur at higher rates than in clinical trials.

Gupta, N; Cullison, C; Mally, A; Xiang, L; Hill, S T; Beveridge, M G

Gupta, N; Cullison, C; Mally, A; Xiang, L; Hill, S T; Beveridge, M G.

Afiliação

Gupta N; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Cullison C; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Mally A; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Xiang L; Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Hill ST; Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
Beveridge MG; Department of Dermatology, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

J Eur Acad Dermatol Venereol ; 35(10): e667-e670, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34014567

Assuntos

Inibidores de Checkpoint Imunológico; Melanoma; Humanos; Imunoterapia; Melanoma/tratamento farmacológico; Receptor de Morte Celular Programada 1/uso terapêutico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Inibidores de Checkpoint Imunológico / Melanoma Limite: Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Assunto da revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google